Key facts
- This page summarizes Pascale Witz's Form 4 filing for Horizon Therapeutics Public Ltd Co.
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 06 Oct 2023, 18:21.
Pascale Witz - 06 Oct 2023 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 06 Oct 2023
- Net transaction value
- -$5,353,292
- SEC form
- 4
- Accepted by SEC
- 06 Oct 2023, 18:21:24 UTC
- Prior SEC filing
- 14 Aug 2023
- Next SEC filing
- 02 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick McIlvenny, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascale Witz filed Form 4 for Horizon Therapeutics Public Ltd Co on 06 Oct 2023.
Change
- Previous filing in this sequence was filed on 14 Aug 2023.
- Current net transaction value: -$5,353,292.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HZNP
transaction
Ordinary Shares
Disposed to Issuer
- Transaction value
- $2,990,788
- Shares
- -25,672
- Change %
- -100%
- Price
- $116.50
- Shares after
- 0
- Date
- 06 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2
HZNP
transaction
Ordinary Shares
Disposed to Issuer
- Transaction value
- $2,362,504
- Shares
- -20,279
- Change %
- -100%
- Price
- $116.50
- Shares after
- 0
- Date
- 06 Oct 2023
- Ownership
- By Trust
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HZNP
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -52,232
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 06 Oct 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 52,232
- Exercise price
- $12.19
- Footnotes
- F3, F4
HZNP
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -32,161
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 06 Oct 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 32,161
- Exercise price
- $13.87
- Footnotes
- F3, F4
HZNP
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -4,016
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 06 Oct 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 4,016
- Exercise price
- Footnotes
- F5, F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Pascale Witz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 7 footnotes
Footnote F1
9,349 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly.
Footnote F2
Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Footnote F3
The Option (as defined in footnote 4 to this Form 4) is fully vested.
Footnote F4
Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
Footnote F5
Each RSU (as defined in footnote 7 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
Footnote F6
The Ordinary Shares subject to the RSUs vest on July 27, 2024.
Footnote F7
Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.